• Je něco špatně v tomto záznamu ?

Inhibition of Lipid Accumulation in Skeletal Muscle and Liver Cells: A Protective Mechanism of Bilirubin Against Diabetes Mellitus Type 2

CA. Hana, EM. Klebermass, T. Balber, M. Mitterhauser, R. Quint, Y. Hirtl, A. Klimpke, S. Somloi, J. Hutz, E. Sperr, P. Eder, J. Jašprová, P. Valášková, L. Vítek, E. Heiss, KH. Wagner

. 2020 ; 11 (-) : 636533. [pub] 20210125

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21010610

Grantová podpora
P 29608 Austrian Science Fund FWF - Austria

Ectopic lipid accumulation in skeletal muscle and liver drives the pathogenesis of diabetes mellitus type 2 (DMT2). Mild hyperbilirubinaemia has been repeatedly suggested to play a role in the prevention of DMT2 and is known for its capacity to shape an improved lipid phenotype in humans and in animals. To date, the effect of bilirubin on lipid accumulation in tissues that are prone to ectopic lipid deposition is unclear. Therefore, we analyzed the effect of bilirubin on lipid accumulation in skeletal muscle and liver cell lines. C2C12 skeletal mouse muscle and HepG2 human liver cells were treated with physiological concentrations of free fatty acids (FFA) (0.5 mM and 1 mM) and unconjugated bilirubin (UCB) (17.1 and 55 µM). The intracellular presence of UCB upon exogenous UCB administration was confirmed by HPLC and the lipid accumulation was assessed by using Nile red. Exposure of both cell lines to UCB significantly reduced lipid accumulation by up to 23% (p ≤ 0.001) in HepG2 and by up to 17% (p ≤ 0.01) in C2C12 cells at 0.5 and 5 h under hypoglycaemic conditions. Simultaneously, UCB slightly increased FFA uptake in HepG2 cells after 0.5 and 5 h and in C2C12 cells after 12 h as confirmed by gas chromatographic analyses of the remaining FFA content in the incubation media. The effects of UCB on lipid accumulation and uptake were abolished in the presence of higher glucose concentrations. Monitoring the uptake of a radiolabeled glucose analogue [18F]FDG: (2-deoxy-2-[18F]fluoro-D-glucose) into both cell types further indicated higher glucose consumption in the presence of UCB. In conclusion, our findings show that UCB considerably decreases lipid accumulation in skeletal muscle and liver cells within a short incubation time of max. 5 h which suggests that mildly elevated bilirubin levels could lower ectopic lipid deposition, a major key element in the pathogenesis of DMT2.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21010610
003      
CZ-PrNML
005      
20210715154733.0
007      
ta
008      
210413s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fphar.2020.636533 $2 doi
035    __
$a (PubMed)33569010
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hana, Claudia A $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
245    10
$a Inhibition of Lipid Accumulation in Skeletal Muscle and Liver Cells: A Protective Mechanism of Bilirubin Against Diabetes Mellitus Type 2 / $c CA. Hana, EM. Klebermass, T. Balber, M. Mitterhauser, R. Quint, Y. Hirtl, A. Klimpke, S. Somloi, J. Hutz, E. Sperr, P. Eder, J. Jašprová, P. Valášková, L. Vítek, E. Heiss, KH. Wagner
520    9_
$a Ectopic lipid accumulation in skeletal muscle and liver drives the pathogenesis of diabetes mellitus type 2 (DMT2). Mild hyperbilirubinaemia has been repeatedly suggested to play a role in the prevention of DMT2 and is known for its capacity to shape an improved lipid phenotype in humans and in animals. To date, the effect of bilirubin on lipid accumulation in tissues that are prone to ectopic lipid deposition is unclear. Therefore, we analyzed the effect of bilirubin on lipid accumulation in skeletal muscle and liver cell lines. C2C12 skeletal mouse muscle and HepG2 human liver cells were treated with physiological concentrations of free fatty acids (FFA) (0.5 mM and 1 mM) and unconjugated bilirubin (UCB) (17.1 and 55 µM). The intracellular presence of UCB upon exogenous UCB administration was confirmed by HPLC and the lipid accumulation was assessed by using Nile red. Exposure of both cell lines to UCB significantly reduced lipid accumulation by up to 23% (p ≤ 0.001) in HepG2 and by up to 17% (p ≤ 0.01) in C2C12 cells at 0.5 and 5 h under hypoglycaemic conditions. Simultaneously, UCB slightly increased FFA uptake in HepG2 cells after 0.5 and 5 h and in C2C12 cells after 12 h as confirmed by gas chromatographic analyses of the remaining FFA content in the incubation media. The effects of UCB on lipid accumulation and uptake were abolished in the presence of higher glucose concentrations. Monitoring the uptake of a radiolabeled glucose analogue [18F]FDG: (2-deoxy-2-[18F]fluoro-D-glucose) into both cell types further indicated higher glucose consumption in the presence of UCB. In conclusion, our findings show that UCB considerably decreases lipid accumulation in skeletal muscle and liver cells within a short incubation time of max. 5 h which suggests that mildly elevated bilirubin levels could lower ectopic lipid deposition, a major key element in the pathogenesis of DMT2.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Klebermass, Eva-Maria $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
700    1_
$a Balber, Theresa $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria ; Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
700    1_
$a Mitterhauser, Markus $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria ; Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
700    1_
$a Quint, Ruth $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
700    1_
$a Hirtl, Yvonne $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
700    1_
$a Klimpke, Antonia $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
700    1_
$a Somloi, Sophie $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
700    1_
$a Hutz, Juliana $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
700    1_
$a Sperr, Elisabeth $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
700    1_
$a Eder, Paulina $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
700    1_
$a Jašprová, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, University General Hospital and 1 Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Valášková, Petra $u Institute of Medical Biochemistry and Laboratory Diagnostics, University General Hospital and 1 Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Vítek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, University General Hospital and 1 Faculty of Medicine, Charles University, Prague, Czechia ; 4 Department of Internal Medicine, University General Hospital and 1 Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Heiss, Elke $u Department of Pharmacognosy, University of Vienna, Vienna, Austria
700    1_
$a Wagner, Karl-Heinz $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
773    0_
$w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 11, č. - (2020), s. 636533
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33569010 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210413 $b ABA008
991    __
$a 20210715154733 $b ABA008
999    __
$a ind $b bmc $g 1649879 $s 1130986
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c - $d 636533 $e 20210125 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
GRA    __
$a P 29608 $p Austrian Science Fund FWF $2 Austria
LZP    __
$a Pubmed-20210413

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...